Startuprad.io: Quantgene can detect early-stage cancer in a single draw of blood
Quantgene is a deep tech startup, working with ai, machine learning, and big data to fight cancer. They describe themselves as a deep genome startup. Quantgene is working on unlocking specific hints about cancer in the human genome since cancer is “encoding” itself into the human genome. Quantgene developed a very specific new capability to unlock the human genome of a very deep level. Startups like 23andme generate averages in genome sequencing, a kind of simplification. Quantgene’s approach, on the other hand, is much more specific, but also very complex. They are looking for dead cancer cells – so-called cell-free DNA – in your blood sample. This only works if they are not working with averages but analyze a single copy of DNA in a sample. They had to develop a vast software infrastructure and their own chemistry to make their idea work.
Quantgene also has an office in Berlin, from which Jo joined the Startuprad.io interview. They call it the “Mustererkennungs Einheit” which means the pattern recognition unit.
Quantgene launches in 2020 (as planned before Corona) first in the USA and within some time they want to launch in Germany, Austria, and Switzerland.